References
- Seligmann H, Podoshin L, Ben David J, Fradis Goldser M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996; 14: 198–212.
- Tsuji K, et al. Temporal bone studies of the human peripheral vestibular system. Aminoglycoside ototoxic-ity. Ann Otol Rhinol Laryngol Suppl 2000; 181: 20–5.
- Rybak LP. Ototoxicity of loop diuretics. Otolaryngol Clin N Am 1993; 26: 829–44.
- Vantrappen G, et al. The ototoxicity of cisplatin: a clinical study. Acta Otorhinolaryngol Belg 1990; 44: 415–21.
- Gendeh BS, et al. Vancomycin administration in con-tinuous ambulatory peritoneal dialysis: the risk of oto-toxicity. Otolaryngol Head Neck Surg 1998; 118: 551–8.
- Brien JA. Ototoxicity associated with salicylates. A brief review. Drug Saf 1993; 9: 143–8.
- Rodman DP, et al. Extended dosage intervals for aminoglycosides. Am J Hosp Farm 1994; 51: 2016–21.
- Barklay ML, et al. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89–98.
- Weatherly RA, et al. Cis-platinum ototoxicity in chil-dren. Laryngoscope 1991; 101: 917–24.
- Morales Angulo C, et al. Non-syndromic familial hear-ing impairment transmitted by mitochondria' inheri-tance. Acta Otorrinolaringol Esp 1999; 50: 93–9.
- Song BB, et al. Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo. J Pharmacol Exp Ther 1997; 228: 369–77.
- Schacht J. Antioxidant therapy attenuates aminogly-coside-induced hearing loss. Ann NY Acad Sci 1999; 884: 125–30.
- Lautermann J, et al. Glutathione protection against gentamicin ototoxicity depends on nutritional status. Hear Res 1995; 86: 15–24.
- Xuan W, Dong M. Effects of compound injection of Pyrola rotundifolia L and Astragalus membranaceus Bge on experimental guinea pigs gentamicin ototoxic-ity. Ann Otol Rhinol Laryngol 1995; 104: 374–80.
- Sha SH, Schacht J. Salicylate attenuates gentamicin-in-duced ototoxicity. Lab Invest 1999; 79: 807–13.
- Suzuki M, et al. Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. Gene Ther 2000; 7: 1046–54.
- Jacobs C, et al. The use of probenecid as a chemopro-tector against cisplatin nephrotoxicity. Cancer 1991; 67: 1518–24.
- Rubin JS, et al. Audiological findings in a phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol 1995; 109: 744–7.
- Gandara DR, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13: 490–6.
- Grau JJ, et al. Calcium supplementation and ototoxic-ity in patients receiving cisplatin. Br J Clin Pharmacol 1996; 42: 233–5.
- Fukaya H, Kanno H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibiinkoka Gakkai Kaiho 1999; 102: 907–17.
- Park KR. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cis-platin ototoxicity in the pediatric population. Ear Hear 1996; 17: 107–15.
- Mulheran M, Degg C. Comparison of distortion product OAE generation between a patient group re-quiring frequent gentamicin therapy and control sub-jects. Br J Audiol 1997; 31: 5–9.
- Kastanioudakis I, et al. Inner ear involvement in rheumatoid arthritis: a prospective clinical study. J Laryngol Otol 1995; 109: 713–8.
- MacAndie CM, O'Reilly BF. Sensorineural hearing loss in chronic otitis media. Clin Otolaryngol 1999; 24: 220–2.